



Joost Boormans

Erasmus MC Cancer Institute, *Rotterdam, The Netherlands*

Dr Joost Boormans attended Medical School at the University of Utrecht, The Netherlands and graduated in 2001. In the same year, he passed the United States Medical Licensing Examination, Step 1 and 2. Following his rotations he was trained as a urologist at the department of Urology of the Erasmus Medical Centre Rotterdam, The Netherlands and affiliated hospitals. He finished his training in December 2009, after which he became a fellow in urological oncology at the department of Urology of Erasmus MC Cancer Institute. In February 2011, he obtained his PhD by successfully defending his thesis on 'Prognostic Implications of Important Genetic Alterations in Prostate Cancer' at the Erasmus University Rotterdam.

He was appointed as a urologist in Rotterdam in July 2011 and initiated the Erasmus MC Bladder Cancer Center as a regional bladder cancer service for the Southwestern part of The Netherlands, which covers a population of 3.0 million. All patients with invasive bladder cancer are multidisciplinary counseled at the Erasmus MC Bladder Cancer Center.

His main clinical interests are bladder cancer, upper tract urothelial cancer, and testicular cancer. He performs both robot-assisted and open pelvic and retroperitoneal surgery. His main research interests are the diagnosis, prognosis, and treatment of urothelial cancer.

He is the Chief Investigator for REBACARE, a national upper tract urothelial cancer trial funded €440,00.- by the Dutch Cancer Society and co-principal investigator in another national bladder cancer trial funded €450,00.- by the Dutch Cancer Society. He is leading a European consortium on the molecular characterization of upper tract urothelial carcinoma funded €960,00.- by TRANSCAN ERA-NET. In addition, he is leading recruiter into national and international bladder cancer trials. He is also a member of the European Association of Urology Testicular Cancer guidelines panel.

He is also a board member of the Erasmus MC Cancer Institute and the Dutch Uro-Oncology Study Group. He has published over 70 peer-reviewed papers in international and national journals, as well as being an invited speaker at national and international meetings on bladder cancer.